淄博下肢层次解剖模型(长治高85CM 语音十四经穴电动针灸模型) (今日更新中)

JIANGYIN, Jiangsu, July 1 (Xinhua) -- China's manned deep-diving submersible, the Jiaolong, embarked on a journey on Friday during which it will make a 5,000-meter dive in the Pacific Ocean.During the dive, the submersible will undergo several operational tests in which it will take photos, shoot video, survey seabeds and take samples from the ocean floor, according to Jin Jiancai, deputy director of the submersible's diving test program team.The tests will be conducted in the Pacific Ocean in accordance with a contract signed between the China Ocean Mineral Resources Research & Development Association and the International Seabed Authority (ISA).The submersible is scheduled to spend 47 days at sea, according to a statement from the Ministry of Science and Technology.A submersible differs from a submarine, as it typically depends on another vessel or facility for support.The Jiaolong, designed to reach a depth of 7,000 meters, completed 17 dives in the South China Sea between May 31 and July 18 last year, reaching 3,759 meters during its deepest dive.In the year since the submersible's last dive, program team members have made several technical improvements to the submersible and its support vessel, Jin said.Jin said the program team members are "very confident" about the test.He also stressed that the test will be carried out in accordance with the provisions of the United Nations Convention on the Law of the Sea as well as the ISA's rules and regulations.The Jiaolong is the world's first manned submersible designed to reach depths of 7,000 meters below sea level, according to Xu Qinan, the submersible's chief designer.

BEIJING, Sept. 14 (Xinhuanet) -- The U.S. Food and Drug Administration (FDA) on Monday announced a recall on a drug infusion pump of Medtronic, the Associated Press reported.The recalled drug pump was called "SynchroMed II", including models of 8637-20 and 8637-40, distributed between 2004 and July 2011.Drug infusion pump was used to deliver the drugs for patients to treat chronic pain, spasms as well as other conditions.The pumps' malfunction could put patients in the risk of either recurrent or withdrawal symptoms, which could be life-threatening, FDA warned.There were 55 reported cases and one death related to the drug withdrawal, among a total 139,653 SynchroMed II pump implants worldwide, FDA notified.The problem was due to a film within the pump's battery that could stop the therapy, FDA said.Medtronic, the U.S. medical technology company based in Minneapolis, is not recommending patients to remove the pumps, but instead, encourage patients to contact their doctor if they hear the device alarm.

SEOUL, Aug. 31 (Xinhua) -- South Korea's infant mortality rate decreased by nearly half in the last 20 years to stand as the world's 16th lowest, a report showed Wednesday.South Korea had an infant mortality rate of 2.2 per 1,000 in 2009, compared with four deaths per 1,000 newborns reported in 1990, the World Health Organization (WHO) and Save the Children, an international non-governmental organization working for children's rights, said in a joint report.With a 45 percent decline in the infant mortality rate, South Korea ranked 16th lowest among WHO member countries, down from its 88th spot in 1990, according to the report. South Korea's infant mortality rate was the same as France, Estonia and Malta. Meanwhile, the Democratic People's Republic of Korea (DPRK) also showed a decline in the infant mortality rate from 23 per 1,000 in 1990 to 18.1 per 1,000 in 2009, but still remained in the lower ranks with 125th place.

LOS ANGELES, June 5 (Xinhua) -- A latest study has found no evidence that screening for ovarian cancer may reduce the risk of dying from the disease, it was reported on Sunday.Screening, however, does increase the likelihood of unnecessary invasive procedures, according to researchers at the University of Utah.The researchers presented their findings at an on-going meeting of the American Society of Clinical Oncology in Chicago, The Los Angeles Times said.Researchers studied 78,216 women, ages 55 to 74, who participated in the National Cancer Institute's Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial. Half of the women received the usual care from their OB-gyns, and half received a CA 125 screening every year for six years and an ultrasound every year for four years. They were then followed for a maximum of 12 years.The researchers observed 212 ovarian cancers in the screened group and 176 in the normal care group. There were 118 ovarian cancer deaths in the screened group and 100 in the normal care group. The differences were not statistically significant. Overall, there were 2,924 deaths from all causes in the screened group and 2,914 in the normal care group.But the researchers also observed that 3,285 women had false- positive diagnoses from the screening. Among those, 1,080 underwent surgery that included an oophorectomy (surgical removal of one or both ovaries). Fifteen percent of those who had surgery developed major complications as a result. Overall, 1,771 women in the screened group (7.7 percent) had an oophorectomy, compared with 1,304 in the normal care group (5.8 percent)."We conclude that annual screening for ovarian cancer ... does not reduce disease-specific mortality in women at average risk for ovarian cancer but does increase invasive medical procedures and associated harms," the researchers said in the study.New data presented at the meeting also showed that the widely used cancer drug Avastin can improve treatment of ovarian cancer, The Times said.About 21,880 American women are diagnosed with ovarian cancer each year and about 13,850 die from it, according to the American Cancer Society. Because it produces few symptoms, the disease is typically not diagnosed until it has become advanced and spread throughout the body. As a result, five-year survival is only about 30 percent, and the disease is one of the five most deadly cancers among women. Being able to detect the cancer at an earlier stage when it might be more curable could thus, theoretically, improve the survival rate.The tests most commonly used to detect ovarian cancer include a transvaginal ultrasound to look for tumor masses and a blood test that screens for increased levels of a tumor marker called CA 125.

SINGAPORE, July 6 (Xinhua) -- A team of researchers in Singapore has designed a tube with special robotic hands that allows doctors to perform surgery on a patient's inner organs without resulting in scars, local media reported on Wednesday.The special "robotic hands" were fixed to the tube to access a patient's stomach. Compared with traditional methods which use only one robotic hand, the new device known as master and slave transluminal endoscopic robot, or MASTER, is more nimble, thereby allowing complex operations, the Lianhe Zaobao reported.Louis Phee, an associate professor at the Nanyang Technological University who led the team of researchers, had spent six years to develop the gadget, which cut an eight-hour procedure to just 17 minutes, said doctors at India's Asian Institute of Gastroenterology.The gadget, still in the trial stage, has been tested earlier this month on three patients at the Indian hospital. It is also expected to be tried out in Germany and China's Hong Kong later. The patients can leave the hospital much sooner than they would have using traditional gadgets.Phee said he expected the gadget to be available on the market as early as three years from now, after going through clinical trials and getting the approval from authorities.He also saw a potential for the gadget to be used on other organs by cutting a small spit on stomach that allows the gadget to go through to access the site.

来源：资阳报